A case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitis

Large-cell carcinoma (LCC) of the lung is defined as an undifferentiated non-small cell lung cancer (NSCLC) and accounts for approximately 7.5% of lung cancers. Immune checkpoint inhibitors (ICIs) may be effective for LCC, but there has been no firm evidence due to its low frequency. We herein repor...

Descripción completa

Detalles Bibliográficos
Autores principales: Ooi, Ryunosuke, Tobino, Kazunori, Sakabe, Mitsukuni, Kawabata, Takafumi, Hiramatsu, Yuri, Sueyasu, Takuto, Yoshimine, Kohei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481563/
https://www.ncbi.nlm.nih.gov/pubmed/32944497
http://dx.doi.org/10.1016/j.rmcr.2020.101197
Descripción
Sumario:Large-cell carcinoma (LCC) of the lung is defined as an undifferentiated non-small cell lung cancer (NSCLC) and accounts for approximately 7.5% of lung cancers. Immune checkpoint inhibitors (ICIs) may be effective for LCC, but there has been no firm evidence due to its low frequency. We herein report an 80-year-old woman with LCC of the lung who was successfully treated with pembrolizumab but developed sclerosing cholangitis as an immune-related adverse event. This case highlights the efficacy of ICIs for LCC as well as the importance of the immediate and detailed management of ICI-related sclerosing cholangitis.

Ejemplares similares